About this trial
Existing guidelines recommend a duration of antibiotic treatment of endocarditis of 4-6 weeks one or more types of intravenously administered antibiotics. The long hospitalization increases several risks for the patient, including mental strain and increased loss of function. Furthermore, it poses a significant financial burden on the health systems. Current guidelines fail to use available clinical and paraclinical, data collected from patients (echo, temperature, CRP, leukocytes, procalcitonin etc.) to determine duration of treatment. A strategy including these data in treatment algorithms ensures an individualized treatment, targeting the individual patient's course and response to treatment. Thus, the purpose of this open-label, prospective, non-inferiority, RCT study is to investigate the safety and effectiveness of shortening treatment of endocarditis based on the individual patient's initial treatment response, sampling 475 patients, approx. 125 patients with each type of bacteria (Streptococci; Enterococcus faecalis; Staphylococcus aureus).
Eligibility criteria
Qualifiers
Admitted with left-sided infectious endocarditis (duke criteria)
< 14 days of relevant antibiotic treatment for endocarditis
One of the following bacteria: Streptococci, enterococcus faecalis, staphylococcus aureus
> 18 years old
Disqualifiers
Known immune incompetency,
Relapse endocarditis with 6 months,
Unable to give informed concent
Trial design
Treatments tested in this trial
- Accelerated antibiotic treatment
- Standard treatment length